Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial.
Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS.
JAMA. 2009 Oct 21;302(15):1651-7.
PMID: 19843899
Conclusions Treatment of patients with CHD and major depression with sertraline and omega-3 fatty acids did not result in superior depression outcomes at 10 weeks, compared with sertraline and placebo. Whether higher doses of omega-3 or sertraline, a different ratio of EPA to DHA, longer treatment, or omega-3 monotherapy can improve depression in patients with CHD remains to be determined